From the Desk of the AAGL President
Since 2014 the AAGL has regularly updated its membership about the issues surrounding tissue extraction at time of benign uterine surgery. With that in mind, we want to inform you of the recent article: “N-of-1 Policymaking—Tragedy, Trade-offs, and the Demise of Morcellation” authored by Dr. Lisa Rosenbaum and published in The New England Journal of Medicine.
She recounts the events starting in 2013 that led up to the FDA actions regarding the use of the morcellator in 2014 and subsequent results. She frames the media discussion that surrounded the morcellation procedure around the theory of “availability cascade,” a phenomena whereby stories inform public perceptions and anyone challenging those perceptions is vilified.*
The AAGL continues its efforts to provide evidence-based information to the FDA and other regulatory bodies affecting our medical specialty. We were pleased to be invited and accepted by the Center for Devices and Radiological Health (CDRH) at the FDA to serve in their Network of Experts. The Network of Experts is a vetted network of outside scientists, clinicians and engineers who provide the FDA with rapid access to scientific, engineering, and medical expertise when it is needed to supplement existing knowledge and expertise within the FDA. This program is designed to broaden exposure to scientific viewpoints, but not to provide external policy advice or opinions.
Please see the AAGL listed on the FDA web site by clicking here.
The AAGL mission has always been one of education—physicians first and then patients, and now we are pleased to be able to educate policymakers.
Arnold P. Advincula, MD, FACOG, FACS
* N Engl J Med 2016; 374:986-990March 10, 2016DOI: 10.1056/NEJMms1516161
Filed under "Association News".